A dose-dense weekly Vs. every 3 week paclitaxel plus carboplatin or the addition of bevacizumab to paclitaxel and carboplatin every 3 week has shown efficacy in ovarian cancer. This article will focus on combination therapy of paclitaxel and carboplatin, weekly Vs. every 3 week with/without bevacizumab. Ovarian cancer is the most lethal gynecological cancer.
Treatment with bevacizumab prolongs progression-free survival but not overall survival. In early-stage breast cancer and metastatic breast cancer patients, weekly paclitaxel therapy has prolonged survival. In patients with ovarian cancer, Japanese investigators have reported that the weekly paclitaxel therapy has prolonged progression-free survival and overall survival in comparison to treatment administrated every 3 weeks. This article will focus on combination therapy of paclitaxel and carboplatin, weekly Vs. every 3 week.…
